MedPath

sefulness of Homoeopathic medicine in Bipolar affective disoder

Phase 2
Conditions
Health Condition 1: F31- Bipolar disorder
Registration Number
CTRI/2024/01/061059
Lead Sponsor
Dr Aiswarya J
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Ages from 18 to 65 years, both sexes who have fulfilled the DSM V criteria for Bipolar 1 disorder.

2.Bipolar 1 disorder with or without psychotic symptoms

Exclusion Criteria

1. Patients with suicidal risks,

2. Pregnant and lactating women,

3. Chronic severe Medical Illness.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cases will be assessed with Born Steiner Irritability scale (BSIS), and Scale for the Assessment of Episodes in Bipolar Disorder (SAEBD)Timepoint: The Born Steiner Irritability scale (BSIS) will be used to assess the cases at the Baseline and every month till the conclusion of the study. <br/ ><br>The Scale for the Assessment of Episodes in Bipolar Disorder (SAEBD) will be used to assess the cases at the Baseline and every three months till the conclusion of the study.
Secondary Outcome Measures
NameTimeMethod
The reduction in frequency of episodes of irritability in Bipolar 1 disorder will be assessed using Born Steiner Irritability scale (BSIS).Timepoint: Cases will be assessed with Born Steiner Irritability scale (BSIS), at the baseline, 3rd, 6th, 9th month and at the conclusion of the study.;The reduction in intensity of irritability in subsequent episodes of Bipolar 1 disorder will be assessed using Born Steiner Irritability scale (BSIS).Timepoint: Cases will be assessed with Born Steiner Irritability scale (BSIS), at the baseline, 3rd, 6th, 9th month and at the conclusion of the study.;The reduction of symptoms of Bipolar 1 disorder will be assessed using SAEBD scale.Timepoint: Cases will be assessed with Scale for the Assessment of Episodes in Bipolar Disorder (SAEBD), at the baseline, 3rd, 6th, 9th month and at the conclusion of the study.
© Copyright 2025. All Rights Reserved by MedPath